Drug Trial Radar · NCT06990776
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 9, 2025
Primary completion
Jul 17, 2025
Study completion Jul 17, 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled phase II study, in which all participants are required to use TQA3605 tablets/placebo in combination with entecavir. The purpose is to evaluate the efficacy and safety of TQA3605 tablets combined with entecavir in treatment-naive chronic HBV-infected subjects. A total of 215 subjects are required.
Conditions
- Chronic Hepatitis B
Interventions
TQA3605 tablets PlaceboDrug
Placebo contains no active substance.
TQA3605 TabletsDrug
TQA3605 tablets is core protein allosteric modulators
Entecavir dispersible tabletsDrug
Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- hepatitis B virus (HBV) DNA <10 IU/mLTime frame: 48 weeks
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, China
Beijing Youan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The Southwest Hospital of AMU
Chongqing, Chongqing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
NanFang Hospital
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
The First Affiliated Hospital of GUANGXI Medical University
Nanning, Guangxi, China
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, China
Zhengzhou No.6 peoples Hospital
Zhengzhou, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
The First Hospital of Changsha
Changsha, Hunan, China
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
Naniing Drum Tower Hospital
Nanjing, Jiangsu, China
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China
The Fifth People's Hospital of Wuxi
Wuxi, Jiangsu, China
Zhenjiang Third People's Hospital
Zhenjiang, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shaanxi, China
Xi'an Jiaotong University Second Affiliated Hospital
Xi'an, Shaanxi, China
The Second Hospital of Shandong University
Jinan, Shandong, China
Shandong Provincial Clinical Center for Public Health
Jinan, Shandong, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Tongren Hospital
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Yiwu Central Hospital
Yiwu, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.